Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

Author: Madison Esely-Kohlman

DDI & Drug Repurposing Article featured in Drug Discovery World (DDW) Spring Edition 2021

Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…

SEKISUI again honored for its ESG management

Every year, the S&P Global Sustainability Yearbook delivers one of the world’s most comprehensive and independent analysis on corporate sustainability. In 2021,...

Meet the Scientist: Stephanie Helmstetter

As part of our Meet the Scientist series, we introduce you to one of our most notable product experts, Stephanie Helmstetter.

Interview with Outsourcing Pharma: Repurposing existing drugs accelerates discovery

“Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an...

Meet the Scientist: Lois Haupt

As part of our Meet the Scientist series, we introduce you to one of our most notable Enzyme Inhibition experts, Lois Haupt.

Updated Look & Fresh Features: Welcome to Our Brand New Website!

We are thrilled to welcome you to the brand new SEKISUI XenoTech website! The reconstruction project is a massive overhaul of over 1,000 pages carefully…

Drug-Drug Interaction (DDI) Prediction Models Following In Vitro Studies in Preclinical Development

In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...

Toxicokinetic (TK) Analysis for Preclinical Drug Development

The main goal of preclinical toxicokinetic (TK) studies is to establish a correlation between a candidate compound’s concentration or dose...

Important DDI Considerations for Repurposing Drugs to Treat COVID-19

“Given the rapid spread of COVID-19 and its relatively high mortality, filling the gap for coronavirus-specific drugs is urgent. […]...

What is DMPK and how does it fit into drug development?

Drug metabolism and pharmacokinetics (DMPK) is a core discipline in drug development that considers the biotransformation of a drug compound...

Meet the Scientist: Pallavi Limaye

We have welcomed a new consultant to the team! Dr. Pallavi Limaye now serves as a Director in the Scientific...

ADME and Drug-Drug Interactions for the Toxicologist

Highlights from the recent webinar presented by our newest expert consultant, Dr. Pallavi Limaye In her recent webinar (now available for...

New TMPRSS2-Expressing Cell Line for COVID-19 Research

We are offering a brand new cell line to assist researchers in the fight against COVID-19.The cell line (JCRB1819), developed...

What is ADME and how does it fit into drug development?

The main aim of drug development is to get a compound that has a therapeutic effect into the form of...

In Vitro Evaluation of Drug-Drug Interaction (DDI) Potential

In its most recent in vitro drug interaction guidance update, the US Food and Drug Administration (FDA) emphasized harmony with the...

Four ways to optimize preclinical in vitro data to mitigate risk of late-stage clinical failure

1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward If you need...

How can in vitro and in vivo studies help me understand my drug’s clearance?

Systemic clearance, denoting how much drug is cleared from a volume of blood per unit of time, is of critical...

Timing of In Vitro Studies: Early, Thorough ADME for Your Compound’s Success

Beyond the need for evidence that a drug works, Food and Drug Administration (FDA) and other regulatory bodies around the...

How Can I Make Sure My Data Meets Regulatory Expectations?

Regulatory authorities publish updated guidance documents that share their expectations for endpoints and test systems with drug developers, but sometimes it is difficult to...

What In Vitro Metabolism and DDI Studies Do I Actually Need?

Though there is no ‘roadmap’ spelling out required studies to achieve regulatory approval for clinical entry, a drug candidate’s metabolism...

I Have My Data… Now What?

As a drug moves through the development pipeline, it undergoes a rigorous battery of safety assessments to prove it will...

The FDA has requested follow-up data… how do I fill in the gaps?

Because each new drug is unique in characteristics, such as chemical structure, mechanism of action, and physicochemical properties, there can...

Cypex Adds Recombinant UGTs

Recombinant enzymes represent a useful test system for studies requiring extra high levels of catalytic activity. Due to high customer demand, Cypex has...

Consultancy Expansion

We are proud to house some of the brightest minds in this field who have seen “the weird stuff” when...

Reduced Pricing for In Vitro Transporter Studies

We’re pleased to announce that our scientists’ ongoing dedication to enhancing our processes and discovering new efficiencies without sacrificing quality...

In Vivo ADME: What You Need and Why You Need It

When putting together a data package for regulatory approval by the FDA, EMA, or PMDA, there is a lot to...

The Story of Us

This year at SEKISUI XenoTech we celebrate our 25th birthday, and our Japan branch turns 64! Looking back over our history,...

Transporters of Emerging Importance in Drug Development: Beyond the Guidance Documents

Dr. Ogilvie’s presentation discussed critical literature and case studies which have been published since the FDA’s most recent guidance revision issued in...

In Vitro Induction Studies: Elements of Design and Important Considerations in Data Analysis

Why do induction studies? Induction potential is an important piece of the drug-drug interaction (DDI) component of an IND submission. Simply put, we...

Official PMDA English Translation

The Japanese regulatory agent PMDA (Pharmaceuticals and Medical Devices Agency) recently published an official English translation of their final Drug Interaction Guideline...

Quality Control is What Makes the Comprehensive Collection of Cell Lines from JCRB Among the Highest Regarded and Most Widely Distributed in the World

About JCRB cell bank In addition to focus on preclinical ADME in vitro testing services and complementary products, SEKISUI XenoTech offers to our...

Minding Your Binding: Plasma Protein Binding Potential Study Now Available at Our US and Japan Labs

While liver and intestine are important in ADME, behavior in blood is also crucial. When an orally administered drug or...

Studies in Japan: Easier & More Beneficial than You Might Think

SEKISUI XenoTech is well-known to pharmaceutical companies and toxicology academics alike for unparalleled experience in quality in vitro ADME/DMPK/DDI studies and complementary...

New Liver Tissue Microarrays Available – What Would Benefit Your Research?

As technology evolves to better meet needs in exploration of drug metabolism pathways and disease mechanisms, familiarization with appropriate and...

Four Ways CROs Drive Innovation for Improved In Vitro Drug Metabolism and Pharmacokinetics (DMPK) Studies

Agility and focused growth allow drug developers to outsource expertise and benefit the industry at-large by fostering innovation. Panelists at the 2021 Annual DMDG Meeting…

DDI & Drug Repurposing Article featured in Drug Discovery World (DDW) Spring Edition 2021

Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…

Important DDI Considerations for Repurposing Drugs to Treat COVID-19

“Given the rapid spread of COVID-19 and its relatively high mortality, filling the gap for coronavirus-specific drugs is urgent. […]...

Missing Out on Annual ‘Comforting of the Soul’

As we begin this summer, many of us are grieving opportunities lost for parties and pool days with friends and...

What is ADME and how does it fit into drug development?

The main aim of drug development is to get a compound that has a therapeutic effect into the form of...

What You Need to Know About Micro-Autoradiography (mARG) Distribution Studies

In vivo determination of drug localization in tissue can be uniquely informative to drug developers investigating distribution within the context of...

Mass Balance Studies: What You Need and Why You Need It

In vivo mass balance studies are an important element of nonclinical drug development, to inform first in-human (FIH) studies and to...

How to Choose the Right Test Systems for Your DMPK Studies

Test systems for DMPK in vitro studies are part of the very foundation of our company. Our labs were borne of...

Can CYP3A4 Induction Predict P-glycoprotein Induction in DDI Studies?

Generally, a drug’s effects on enzyme and transporter activity are examined independently in a drug development program, but what if...

In Vivo ADME: What You Need and Why You Need It

When putting together a data package for regulatory approval by the FDA, EMA, or PMDA, there is a lot to...

Cell Handling & Media Selection for Best Results in Hepatocyte Assays

Getting reliable, reproducible results from studies using hepatocytes as a model system for drug metabolism is in part dependent on how well...

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate